Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jennifer Ruth Brown, Ph.D., M.D.

Title
Institution
Department
Address
Fax

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01CA213442 (BROWN, JENNIFER R) Mar 1, 2017 - Feb 28, 2022
    NIH/NCI
    Unlocking the Potential of PI3K Inhibition in CLL
    Role: Principal Investigator
  2. P01CA206978 (WU, CATHERINE JU-YING) Sep 1, 2016 - Aug 31, 2021
    NIH/NCI
    Comprehensive dissection of the CLL genome and phenome to improve patient outcomes
    Role: Co-Principal Investigator
  3. K23CA115682 (BROWN, JENNIFER R) Jul 1, 2005 - Jul 31, 2010
    NIH/NCI
    Genetic Alterations in Families with Multiple Lymphomas
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Kim HT, Ahn KW, Hu ZH, Davids MS, Volpe VO, Antin JH, Sorror ML, Shadman M, Press O, Pidala J, Hogan W, Negrin R, Devine S, Uberti J, Agura E, Nash R, Mehta J, McGuirk J, Forman S, Langston A, Giralt SA, Perales MA, Battiwalla M, Hale GA, Gale RP, Marks DI, Hamadani M, Ganguly S, Bacher U, Lazarus H, Reshef R, Hildebrandt GC, Inamoto Y, Cahn JY, Solh M, Kharfan-Dabaja MA, Ghosh N, Saad A, Aljurf M, Schouten HC, Hill BT, Pawarode A, Kindwall-Keller T, Saba N, Copelan EA, Nathan S, Beitinjaneh A, Savani BN, Cerny J, Grunwald MR, Yared J, Wirk BM, Nishihori T, Chhabra S, Olsson RF, Bashey A, Gergis U, Popat U, Sobecks R, Alyea E, Saber W, Brown JR. Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. Clin Cancer Res. 2019 Jun 28. PMID: 31253630.
    Citations:    
  2. Davids MS, Brander DM, Kim HT, Tyekucheva S, Bsat J, Savell A, Hellman JM, Bazemore J, Francoeur K, Alencar A, Shune L, Omaira M, Jacobson CA, Armand P, Ng S, Crombie J, LaCasce AS, Arnason J, Hochberg EP, Takvorian RW, Abramson JS, Fisher DC, Brown JR. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2019 Jun 13. PMID: 31208944.
    Citations:    
  3. Gruber M, Bozic I, Leshchiner I, Livitz D, Stevenson K, Rassenti L, Rosebrock D, Taylor-Weiner A, Olive O, Goyetche R, Fernandes SM, Sun J, Stewart C, Wong A, Cibulskis C, Zhang W, Reiter JG, Gerold JM, Gribben JG, Rai KR, Keating MJ, Brown JR, Neuberg D, Kipps TJ, Nowak MA, Getz G, Wu CJ. Growth dynamics in naturally progressing chronic lymphocytic leukaemia. Nature. 2019 Jun; 570(7762):474-479. PMID: 31142838.
    Citations:    
  4. Awan FT, Schuh A, Brown JR, Furman RR, Pagel JM, Hillmen P, Stephens DM, Woyach J, Bibikova E, Charuworn P, Frigault MM, Hamdy A, Izumi R, Linghu B, Patel P, Wang MH, Byrd JC. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv. 2019 May 14; 3(9):1553-1562. PMID: 31088809.
    Citations:    
  5. Soumerai JD, Davids MS, Werner L, Fisher DC, Armand P, Amrein PC, Neuberg D, Hochberg EP, Brown JR, Abramson JS. Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2019 May 10; 1-8. PMID: 31074316.
    Citations:    
  6. Lampson BL, Kim HT, Davids MS, Abramson JS, Freedman AS, Jacobson CA, Armand PA, Joyce RM, Arnason JE, Rassenti LZ, Kipps TJ, Fein J, Fernandes SM, Hanna JR, Fisher DC, Brown JR. Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. Blood Adv. 2019 Apr 09; 3(7):1167-1174. PMID: 30967392.
    Citations:    
  7. Deshields TL, Dueck AC, Rogers K, Brown JR, Shanafelt T, Mintzer D, Byrd JC. Perceived risk for cancer progression and psychological status in chronic lymphocytic leukemia patients: CALGB 70603 (Alliance). Leuk Lymphoma. 2019 Mar 27; 1-4. PMID: 30916608.
    Citations:    
  8. O'Brien SM, Byrd JC, Hillmen P, Coutre S, Brown JR, Barr PM, Barrientos JC, Devereux S, Robak T, Reddy NM, Kipps TJ, Tedeschi A, Cymbalista F, Ghia P, Chang S, Ninomoto J, James DF, Burger JA. Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. Am J Hematol. 2019 May; 94(5):554-562. PMID: 30767298.
    Citations:    
  9. Byrd JC, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Thornton P, Moreno C, Montillo M, Pagel JM, Burger JA, Woyach JA, Dai S, Vezan R, James DF, Brown JR. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood. 2019 May 09; 133(19):2031-2042. PMID: 30842083.
    Citations:    
  10. Brown JR, O'Brien S, Kingsley CD, Eradat H, Pagel JM, Hirata J, McIver T, Morariu-Zamfir R, Kipps TJ. Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL. Blood. 2019 Feb 28; 133(9):990-992. PMID: 30593446.
    Citations:    Fields:    
  11. Davids MS, Kim HT, Nicotra A, Savell A, Francoeur K, Hellman JM, Bazemore J, Miskin HP, Sportelli P, Stampleman L, Maegawa R, Rueter J, Boruchov AM, Arnason JE, Jacobson CA, Jacobsen ED, Fisher DC, Brown JR. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study. Lancet Haematol. 2019 Jan; 6(1):e38-e47. PMID: 30558987.
    Citations:    Fields:    
  12. Improgo MR, Tesar B, Klitgaard JL, Magori-Cohen R, Yu L, Kasar S, Chaudhary D, Miao W, Fernandes SM, Hoang K, Westlin WF, Kim HT, Brown JR. MYD88 L265P mutations identify a prognostic gene expression signature and a pathway for targeted inhibition in CLL. Br J Haematol. 2019 Mar; 184(6):925-936. PMID: 30537114.
    Citations:    Fields:    
  13. Kater AP, Brown JR. Ibrutinib: searching for a partner drug. Lancet Oncol. 2019 Jan; 20(1):3-5. PMID: 30522966.
    Citations:    Fields:    
  14. Brown JR, Moslehi J, Ewer MS, O'Brien SM, Ghia P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Coutre SE, Dilhuydy MS, Cramer P, Jaeger U, Dreyling M, Byrd JC, Treon S, Liu EY, Chang S, Bista A, Vempati R, Boornazian L, Valentino R, Reddy V, Mahler M, Yang H, Graef T, Burger JA. Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. Br J Haematol. 2019 Feb; 184(4):558-569. PMID: 30506764.
    Citations:    Fields:    
  15. Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Coutre S, Hurria A, Brown JR, Lozanski G, Blachly JS, Ozer HG, Major-Elechi B, Fruth B, Nattam S, Larson RA, Erba H, Litzow M, Owen C, Kuzma C, Abramson JS, Little RF, Smith SE, Stone RM, Mandrekar SJ, Byrd JC. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med. 2018 12 27; 379(26):2517-2528. PMID: 30501481.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  16. Brown JR. Relapsed CLL: sequencing, combinations, and novel agents. Hematology Am Soc Hematol Educ Program. 2018 11 30; 2018(1):248-255. PMID: 30504318.
    Citations:    Fields:    Translation:Humans
  17. Ott CJ, Federation AJ, Schwartz LS, Kasar S, Klitgaard JL, Lenci R, Li Q, Lawlor M, Fernandes SM, Souza A, Polaski D, Gadi D, Freedman ML, Brown JR, Bradner JE. Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia. Cancer Cell. 2018 Dec 10; 34(6):982-995.e7. PMID: 30503705.
    Citations:    Fields:    
  18. Dong S, Harrington BK, Hu EY, Greene JT, Lehman AM, Tran M, Wasmuth RL, Long M, Muthusamy N, Brown JR, Johnson AJ, Byrd JC. PI3K p110d inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression. J Clin Invest. 2019 Jan 02; 129(1):122-136. PMID: 30457982.
    Citations:    Fields:    
  19. Davids MS, Kim HT, Yu L, De Maeyer G, McDonough M, Vartanov AR, Langey R, Fernandes SM, Hellman JM, Francoeur K, Arnason J, Jacobsen ED, LaCasce AS, Fisher DC, Brown JR. Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia. Leuk Lymphoma. 2019 May; 60(5):1312-1315. PMID: 30322319.
    Citations:    Fields:    
  20. Barrientos JC, O'Brien S, Brown JR, Kay NE, Reddy NM, Coutre S, Tam C, Mulligan S, Jaeger U, Devereux S, Pocock C, Robak T, Schuster SJ, Schuh A, Gill D, Bloor A, Dearden C, Moreno C, Cull G, Hamblin M, Jones JA, Eckert K, Solman IG, Suzuki S, Hsu E, James DF, Byrd JC, Hillmen P. Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clin Lymphoma Myeloma Leuk. 2018 Dec; 18(12):803-813.e7. PMID: 30249389.
    Citations:    Fields:    
  21. Tam CS, Brown JR. Vigilance for ibrutinib-associated ventricular arrhythmias: rare but be aware. Leuk Lymphoma. 2018 12; 59(12):2767-2768. PMID: 30032684.
    Citations:    Fields:    
  22. Brown JR. Still a role for second-line chemoimmunotherapy in chronic lymphocytic leukemia? Haematologica. 2018 07; 103(7):1096-1098. PMID: 29970493.
    Citations:    Fields:    
  23. Brown JR. Ibrutinib: coming of age? Blood. 2018 04 26; 131(17):1880-1882. PMID: 29699993.
    Citations:    Fields:    
  24. Brown JR, Hamadani M, Hayslip J, Janssens A, Wagner-Johnston N, Ottmann O, Arnason J, Tilly H, Millenson M, Offner F, Gabrail NY, Ganguly S, Ailawadhi S, Kasar S, Kater AP, Doorduijn JK, Gao L, Lager JJ, Wu B, Egile C, Kersten MJ. Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. Lancet Haematol. 2018 Apr; 5(4):e170-e180. PMID: 29550382.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  25. Nørgaard CH, Jakobsen LH, Gentles AJ, Dybkær K, El-Galaly TC, Bødker JS, Schmitz A, Johansen P, Herold T, Spiekermann K, Brown JR, Klitgaard JL, Johnsen HE, Bøgsted M. Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow - A proof of concept study. PLoS One. 2018; 13(3):e0193249. PMID: 29513759.
    Citations:    
  26. Lampson BL, Brown JR. Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia? Expert Rev Hematol. 2018 03; 11(3):185-194. PMID: 29381098.
    Citations: 1     Fields:    Translation:HumansAnimals
  27. Dang A, De Leo S, Bogdanowicz DR, Yuan DJ, Fernandes SM, Brown JR, Lu HH, Kam LC. Enhanced activation and expansion of T cells using mechanically soft elastomer fibers. Adv Biosyst. 2018 Feb; 2(2). PMID: 31008184.
    Citations:    
  28. Brown JR. How I treat CLL patients with ibrutinib. Blood. 2018 01 25; 131(4):379-386. PMID: 29255067.
    Citations: 4     Fields:    
  29. Brown JR, Cymbalista F, Sharman J, Jacobs I, Nava-Parada P, Mato A. The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars. Oncologist. 2018 Mar; 23(3):288-296. PMID: 29212732.
    Citations: 1     Fields:    
  30. Itchaki G, Brown JR. Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia. Ther Adv Hematol. 2018 Jan; 9(1):3-19. PMID: 29317997.
    Citations: 1     
  31. Aw A, Kim HT, Fernandes SM, Hoang K, Kasar S, Faham M, Brown JR. Minimal residual disease detected by immunoglobulin sequencing predicts CLL relapse more effectively than flow cytometry. Leuk Lymphoma. 2018 08; 59(8):1986-1989. PMID: 29164966.
    Citations:    Fields:    
  32. Brown JR, Kay NE. Reply to S. Opat et al. J Clin Oncol. 2017 12 20; 35(36):4094-4095. PMID: 29099631.
    Citations:    Fields:    
  33. Tiao G, Improgo MR, Tausch E, Fernandes SM, Bahlo J, Robrecht S, Fischer K, Hallek M, Stilgenbauer S, Kiezun A, Getz G, Brown JR. Analysis of ITGB2 rare germ line variants in chronic lymphocytic leukemia. Blood. 2017 11 30; 130(22):2443-2444. PMID: 29051179.
    Citations:    Fields:    Translation:HumansCells
  34. Chai-Adisaksopha C, Brown JR. FCR achieves long-term durable remissions in patients with IGHV-mutated CLL. Blood. 2017 11 23; 130(21):2278-2282. PMID: 29025740.
    Citations: 1     Fields:    Translation:HumansCells
  35. Lampson BL, Brown JR. PI3Kd-selective and PI3Ka/d-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. Expert Opin Investig Drugs. 2017 Nov; 26(11):1267-1279. PMID: 28945111.
    Citations: 1     Fields:    Translation:HumansAnimals
  36. Arnason JE, Brown JR. Targeting B Cell Signaling in Chronic Lymphocytic Leukemia. Curr Oncol Rep. 2017 Sep; 19(9):61. PMID: 28755313.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  37. Brown JR, Moslehi J, O'Brien S, Ghia P, Hillmen P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Kipps TJ, Coutre S, Dilhuydy MS, Cramer P, Tedeschi A, Jaeger U, Dreyling M, Byrd JC, Howes A, Todd M, Vermeulen J, James DF, Clow F, Styles L, Valentino R, Wildgust M, Mahler M, Burger JA. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017 10; 102(10):1796-1805. PMID: 28751558.
    Citations: 8     Fields:    Translation:Humans
  38. Brown JR, Kay NE. Chemoimmunotherapy Is Not Dead Yet in Chronic Lymphocytic Leukemia. J Clin Oncol. 2017 09 10; 35(26):2989-2992. PMID: 28742455.
    Citations:    Fields:    
  39. Gordon MJ, Lewis LD, Brown JR, Danilov AV. Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose? Expert Rev Hematol. 2017 08; 10(8):707-718. PMID: 28664772.
    Citations:    Fields:    Translation:Humans
  40. Wang L, Fan J, Francis JM, Georghiou G, Hergert S, Li S, Gambe R, Zhou CW, Yang C, Xiao S, Cin PD, Bowden M, Kotliar D, Shukla SA, Brown JR, Neuberg D, Alessi DR, Zhang CZ, Kharchenko PV, Livak KJ, Wu CJ. Integrated single-cell genetic and transcriptional analysis suggests novel drivers of chronic lymphocytic leukemia. Genome Res. 2017 08; 27(8):1300-1311. PMID: 28679620.
    Citations: 2     Fields:    Translation:HumansCells
  41. Aw A, Brown JR. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies. Drugs Aging. 2017 07; 34(7):509-527. PMID: 28536906.
    Citations: 3     Fields:    Translation:HumansCells
  42. Aw A, Brown JR. The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia. Leuk Lymphoma. 2017 Oct; 58(10):2287-2297. PMID: 28482721.
    Citations: 1     Fields:    
  43. Itchaki G, Brown JR. Lenalidomide in the treatment of chronic lymphocytic leukemia. Expert Opin Investig Drugs. 2017 May; 26(5):633-650. PMID: 28388253.
    Citations: 1     Fields:    Translation:Humans
  44. Barr PM, Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Mulligan SP, Jaeger U, Furman RR, Cymbalista F, Montillo M, Dearden C, Robak T, Moreno C, Pagel JM, Burger JA, Suzuki S, Sukbuntherng J, Cole G, James DF, Byrd JC. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood. 2017 05 11; 129(19):2612-2615. PMID: 28373262.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  45. Jones JA, Robak T, Brown JR, Awan FT, Badoux X, Coutre S, Loscertales J, Taylor K, Vandenberghe E, Wach M, Wagner-Johnston N, Ysebaert L, Dreiling L, Dubowy R, Xing G, Flinn IW, Owen C. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Haematol. 2017 Mar; 4(3):e114-e126. PMID: 28257752.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  46. Lampson BL, Yu L, Glynn RJ, Barrientos JC, Jacobsen ED, Banerji V, Jones JA, Walewska R, Savage KJ, Michaud GF, Moslehi JJ, Brown JR. Ventricular arrhythmias and sudden death in patients taking ibrutinib. Blood. 2017 05 04; 129(18):2581-2584. PMID: 28223277.
    Citations: 8     Fields:    Translation:Humans
  47. Compagno M, Wang Q, Pighi C, Cheong TC, Meng FL, Poggio T, Yeap LS, Karaca E, Blasco RB, Langellotto F, Ambrogio C, Voena C, Wiestner A, Kasar SN, Brown JR, Sun J, Wu CJ, Gostissa M, Alt FW, Chiarle R. Phosphatidylinositol 3-kinase d blockade increases genomic instability in B cells. Nature. 2017 02 23; 542(7642):489-493. PMID: 28199309.
    Citations: 19     Fields:    Translation:HumansAnimalsCells
  48. Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M, Ghia P, Illés Á, Jurczak W, Marlton P, Montillo M, Morschhauser F, Pristupa AS, Robak T, Sharman JP, Simpson D, Smolej L, Tausch E, Adewoye AH, Dreiling LK, Kim Y, Stilgenbauer S, Hillmen P. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017 03; 18(3):297-311. PMID: 28139405.
    Citations: 20     Fields:    Translation:HumansCTClinical Trials
  49. Cui B, Ghia EM, Chen L, Rassenti LZ, DeBoever C, Widhopf GF, Yu J, Neuberg DS, Wierda WG, Rai KR, Kay NE, Brown JR, Jones JA, Gribben JG, Frazer KA, Kipps TJ. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. Blood. 2016 12 22; 128(25):2931-2940. PMID: 27815263.
    Citations: 12     Fields:    Translation:HumansCells
  50. Wang L, Brooks AN, Fan J, Wan Y, Gambe R, Li S, Hergert S, Yin S, Freeman SS, Levin JZ, Fan L, Seiler M, Buonamici S, Smith PG, Chau KF, Cibulskis CL, Zhang W, Rassenti LZ, Ghia EM, Kipps TJ, Fernandes S, Bloch DB, Kotliar D, Landau DA, Shukla SA, Aster JC, Reed R, DeLuca DS, Brown JR, Neuberg D, Getz G, Livak KJ, Meyerson MM, Kharchenko PV, Wu CJ. Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia. Cancer Cell. 2016 Nov 14; 30(5):750-763. PMID: 27818134.
    Citations: 13     Fields:    Translation:HumansCells
  51. Ryan CE, Sahaf B, Logan AC, O'Brien S, Byrd JC, Hillmen P, Brown JR, Dyer MJ, Mato AR, Keating MJ, Jaglowski S, Clow F, Rezvani AR, Styles L, Coutre SE, Miklos DB. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood. 2016 12 22; 128(25):2899-2908. PMID: 27802969.
    Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
  52. Herrera AF, Mei M, Low L, Kim HT, Griffin GK, Song JY, Merryman RW, Bedell V, Pak C, Sun H, Paris T, Stiller T, Brown JR, Budde LE, Chan WC, Chen R, Davids MS, Freedman AS, Fisher DC, Jacobsen ED, Jacobson CA, LaCasce AS, Murata-Collins J, Nademanee AP, Palmer JM, Pihan GA, Pillai R, Popplewell L, Siddiqi T, Sohani AR, Zain J, Rosen ST, Kwak LW, Weinstock DM, Forman SJ, Weisenburger DD, Kim Y, Rodig SJ, Krishnan A, Armand P. Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. J Clin Oncol. 2017 Jan; 35(1):24-31. PMID: 28034071.
    Citations: 4     Fields:    Translation:Humans
  53. Kharfan-Dabaja MA, Kumar A, Hamadani M, Stilgenbauer S, Ghia P, Anasetti C, Dreger P, Montserrat E, Perales MA, Alyea EP, Awan FT, Ayala E, Barrientos JC, Brown JR, Castro JE, Furman RR, Gribben J, Hill BT, Mohty M, Moreno C, O'Brien S, Pavletic SZ, Pinilla-Ibarz J, Reddy NM, Sorror M, Bredeson C, Carpenter P, Savani BN. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2016 12; 22(12):2117-2125. PMID: 27660167.
    Citations: 4     Fields:    Translation:Humans
  54. O'Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, Österborg A, Siddiqi T, Thirman MJ, Furman RR, Ilhan O, Keating MJ, Call TG, Brown JR, Stevens-Brogan M, Li Y, Clow F, James DF, Chu AD, Hallek M, Stilgenbauer S. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016 Oct; 17(10):1409-1418. PMID: 27637985.
    Citations: 28     Fields:    Translation:HumansCellsCTClinical Trials
  55. Liu X, Wang A, Liang X, Liu J, Zou F, Chen C, Zhao Z, Deng Y, Wu H, Qi Z, Wang B, Wang L, Liu F, Xu Y, Wang W, Fernandes SM, Stone RM, Galinsky IA, Brown JR, Loh T, Griffin JD, Zhang S, Weisberg EL, Zhang X, Liu J, Liu Q. Simultaneous inhibition of Vps34 kinase would enhance PI3Kd inhibitor cytotoxicity in the B-cell malignancies. Oncotarget. 2016 Aug 16; 7(33):53515-53525. PMID: 27447747.
    Citations: 2     Fields:    Translation:HumansAnimals
  56. Yu L, Kim HT, Kasar S, Benien P, Du W, Hoang K, Aw A, Tesar B, Improgo R, Fernandes S, Radhakrishnan S, Klitgaard J, Lee C, Getz G, Setlur SR, Brown JR. Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation. Clin Cancer Res. 2017 Feb 01; 23(3):735-745. PMID: 27503198.
    Citations: 9     Fields:    Translation:HumansCells
  57. Ferguson FM, Ni J, Zhang T, Tesar B, Sim T, Kim ND, Deng X, Brown JR, Zhao JJ, Gray NS. Discovery of a Series of 5,11-Dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-ones as Selective PI3K-d/? Inhibitors. ACS Med Chem Lett. 2016 Oct 13; 7(10):908-912. PMID: 27774127.
    Citations: 1     
  58. Pavlasova G, Borsky M, Seda V, Cerna K, Osickova J, Doubek M, Mayer J, Calogero R, Trbusek M, Pospisilova S, Davids MS, Kipps TJ, Brown JR, Mraz M. Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. Blood. 2016 09 22; 128(12):1609-13. PMID: 27480113.
    Citations: 6     Fields:    Translation:HumansCells
  59. Dubuc AM, Davids MS, Pulluqi M, Pulluqi O, Hoang K, Hernandez-Sánchez JM, Schlich C, Hernández-Rivas JM, Brown JR, Dal Cin P. FISHing in the dark: How the combination of FISH and conventional karyotyping improves the diagnostic yield in CpG-stimulated chronic lymphocytic leukemia. Am J Hematol. 2016 10; 91(10):978-83. PMID: 27341486.
    Citations: 3     Fields:    Translation:HumansCells
  60. Danilov AV, Lewis LD, Lansigan F, Roudaia L, Findley DL, Jones SY, Highhouse B, Beaulieu BB, Brown JR. A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities. Br J Haematol. 2017 09; 178(5):820-823. PMID: 27377970.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  61. Liu X, Wang A, Liang X, Chen C, Liu J, Zhao Z, Wu H, Deng Y, Wang L, Wang B, Wu J, Liu F, Fernandes SM, Adamia S, Stone RM, Galinsky IA, Brown JR, Griffin JD, Zhang S, Loh T, Zhang X, Wang W, Weisberg EL, Liu J, Liu Q. Characterization of selective and potent PI3Kd inhibitor (PI3KDIN- 015) for B-Cell malignances. Oncotarget. 2016 May 31; 7(22):32641-51. PMID: 27081697.
    Citations: 1     Fields:    Translation:HumansCells
  62. Lampson BL, Kasar SN, Matos TR, Morgan EA, Rassenti L, Davids MS, Fisher DC, Freedman AS, Jacobson CA, Armand P, Abramson JS, Arnason JE, Kipps TJ, Fein J, Fernandes S, Hanna J, Ritz J, Kim HT, Brown JR. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016 07 14; 128(2):195-203. PMID: 27247136.
    Citations: 41     Fields:    Translation:HumansCTClinical Trials
  63. Thijssen R, Ter Burg J, Garrick B, van Bochove GG, Brown JR, Fernandes SM, Rodríguez MS, Michot JM, Hallek M, Eichhorst B, Reinhardt HC, Bendell J, Derks IA, van Kampen RJ, Hege K, Kersten MJ, Trowe T, Filvaroff EH, Eldering E, Kater AP. Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. Blood. 2016 07 28; 128(4):574-83. PMID: 27235137.
    Citations:    
  64. Burger JA, Landau DA, Taylor-Weiner A, Bozic I, Zhang H, Sarosiek K, Wang L, Stewart C, Fan J, Hoellenriegel J, Sivina M, Dubuc AM, Fraser C, Han Y, Li S, Livak KJ, Zou L, Wan Y, Konoplev S, Sougnez C, Brown JR, Abruzzo LV, Carter SL, Keating MJ, Davids MS, Wierda WG, Cibulskis K, Zenz T, Werner L, Dal Cin P, Kharchencko P, Neuberg D, Kantarjian H, Lander E, Gabriel S, O'Brien S, Letai A, Weitz DA, Nowak MA, Getz G, Wu CJ. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016 05 20; 7:11589. PMID: 27199251.
    Citations: 32     Fields:    Translation:Humans
  65. Brown JR, Harb WA, Hill BT, Gabrilove J, Sharman JP, Schreeder MT, Barr PM, Foran JM, Miller TP, Burger JA, Kelly KR, Mahadevan D, Ma S, Li Y, Pierce DW, Barnett E, Marine J, Miranda M, Azaryan A, Yu X, Nava-Parada P, Mei J, Kipps TJ. Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia. Haematologica. 2016 07; 101(7):e295-8. PMID: 27151992.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  66. Yang G, Buhrlage SJ, Tan L, Liu X, Chen J, Xu L, Tsakmaklis N, Chen JG, Patterson CJ, Brown JR, Castillo JJ, Zhang W, Zhang X, Liu S, Cohen P, Hunter ZR, Gray N, Treon SP. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Blood. 2016 06 23; 127(25):3237-52. PMID: 27143257.
    Citations: 4     Fields:    Translation:HumansCells
  67. Anderson MA, Deng J, Seymour JF, Tam C, Kim SY, Fein J, Yu L, Brown JR, Westerman D, Si EG, Majewski IJ, Segal D, Heitner Enschede SL, Huang DC, Davids MS, Letai A, Roberts AW. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood. 2016 06 23; 127(25):3215-24. PMID: 27069256.
    Citations: 25     Fields:    Translation:HumansAnimalsCells
  68. Chang DK, Kurella VB, Biswas S, Avnir Y, Sui J, Wang X, Sun J, Wang Y, Panditrao M, Peterson E, Tallarico A, Fernandes S, Goodall M, Zhu Q, Brown JR, Jefferis R, Marasco WA. Humanized mouse G6 anti-idiotypic monoclonal antibody has therapeutic potential against IGHV1-69 germline gene-based B-CLL. MAbs. 2016 May-Jun; 8(4):787-98. PMID: 26963739.
    Citations: 2     Fields:    Translation:HumansAnimals
  69. Roccaro AM, Sacco A, Shi J, Chiarini M, Perilla-Glen A, Manier S, Glavey S, Aljawai Y, Mishima Y, Kawano Y, Moschetta M, Correll M, Improgo MR, Brown JR, Imberti L, Rossi G, Castillo JJ, Treon SP, Freedman ML, Van Allen EM, Hide W, Hiller E, Rainville I, Ghobrial IM. Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia. Blood. 2016 05 26; 127(21):2598-606. PMID: 26903547.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  70. Brown JR. The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia. Semin Oncol. 2016 Apr; 43(2):260-4. PMID: 27040704.
    Citations: 9     Fields:    Translation:HumansAnimalsCells
  71. Armand P, Redd R, Bsat J, Mayuram S, Giardino A, Fisher DC, LaCasce AS, Jacobson C, Davids MS, Brown JR, Weng L, Wilkins J, Faham M, Freedman AS, Joyce R, Jacobsen ED. A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma. Br J Haematol. 2016 Apr; 173(1):89-95. PMID: 26729345.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  72. Brown JR, Hallek MJ, Pagel JM. Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination? Am Soc Clin Oncol Educ Book. 2016; 35:e387-98. PMID: 27249745.
    Citations: 6     Fields:    Translation:Humans
  73. Xu L, Hunter ZR, Tsakmaklis N, Cao Y, Yang G, Chen J, Liu X, Kanan S, Castillo JJ, Tai YT, Zehnder JL, Brown JR, Carrasco RD, Advani R, Sabile JM, Argyropoulos K, Lia Palomba M, Morra E, Trojani A, Greco A, Tedeschi A, Varettoni M, Arcaini L, Munshi NM, Anderson KC, Treon SP. Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia. Br J Haematol. 2016 Mar; 172(5):735-44. PMID: 26659815.
    Citations: 13     Fields:    Translation:Humans
  74. Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016 Jan 28; 374(4):323-32. PMID: 26641137.
    Citations: 77     Fields:    Translation:HumansCTClinical Trials
  75. Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Kipps TJ, Anderson MA, Brown JR, Gressick L, Wong S, Dunbar M, Zhu M, Desai MB, Cerri E, Heitner Enschede S, Humerickhouse RA, Wierda WG, Seymour JF. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016 Jan 28; 374(4):311-22. PMID: 26639348.
    Citations: 194     Fields:    Translation:HumansCTClinical Trials
  76. Paiva C, Godbersen JC, Soderquist RS, Rowland T, Kilmarx S, Spurgeon SE, Brown JR, Srinivasa SP, Danilov AV. Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells. PLoS One. 2015; 10(11):e0143685. PMID: 26606677.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  77. Hung OY, Brown JR, Dai T, Easley KA, Flowers CR, Parashar S. Pattern of cardiac surveillance among patients with lymphoma receiving anthracycline-based chemotherapy. BMJ Open. 2015 Oct 06; 5(10):e008350. PMID: 26443656.
    Citations: 1     Fields:    Translation:HumansPHPublic Health
  78. Flowers CR, Brown JR, Rosenthal H, Stock W, Katzen HI, Cohen JB, Sinha R, Lakhanpal S, Leis JF, Waller EK, Jaye DL. A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2015 Nov; 15(11):694-8. PMID: 26385641.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  79. Brown JR. The rosy future of BCL-2 inhibition in chronic lymphocytic leukemia: pursuit of a worthy target. Leuk Lymphoma. 2015; 56(10):2755-6. PMID: 25971908.
    Citations:    Fields:    Translation:Humans
  80. Brown JR, Tesar B, Yu L, Werner L, Takebe N, Mikler E, Reynolds HM, Thompson C, Fisher DC, Neuberg D, Freedman AS. Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia. Leuk Lymphoma. 2015; 56(12):3336-42. PMID: 25971907.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  81. Davids MS, Vartanov A, Werner L, Neuberg D, Dal Cin P, Brown JR. Controversial fluorescence in situ hybridization cytogenetic abnormalities in chronic lymphocytic leukaemia: new insights from a large cohort. Br J Haematol. 2015 Sep; 170(5):694-703. PMID: 26032737.
    Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
  82. Brown JR. Optimal First-Line Therapy for Previously Untreated Chronic Lymphocytic Leukemia: The Case for Chemotherapy. Oncology (Williston Park). 2015 Jun; 29(6):442, 444. PMID: 26091679.
    Citations:    Fields:    Translation:Humans
  83. Coutré SE, Barrientos JC, Brown JR, de Vos S, Furman RR, Keating MJ, Li D, O'Brien SM, Pagel JM, Poleski MH, Sharman JP, Yao NS, Zelenetz AD. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015; 56(10):2779-86. PMID: 25726955.
    Citations: 44     Fields:    Translation:HumansCells
  84. Godbersen JC, Paiva C, Danilova OV, Berger A, Brown JR, Danilov AV. Targeting neddylation effectively antagonizes nuclear factor-?B in chronic lymphocytic leukemia B-cells. Leuk Lymphoma. 2015 May; 56(5):1566-9. PMID: 26086969.
    Citations: 2     Fields:    Translation:HumansCells
  85. Brown JR, Davids MS, Rodon J, Abrisqueta P, Kasar SN, Lager J, Jiang J, Egile C, Awan FT. Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma. Clin Cancer Res. 2015 Jul 15; 21(14):3160-9. PMID: 25840972.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  86. Brown JR, O'Brien S, Kingsley CD, Eradat H, Pagel JM, Lymp J, Hirata J, Kipps TJ. Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial. Blood. 2015 Apr 30; 125(18):2779-85. PMID: 25769620.
    Citations: 19     Fields:    Translation:HumansCTClinical Trials
  87. Brown JR, Barrientos JC, Barr PM, Flinn IW, Burger JA, Tran A, Clow F, James DF, Graef T, Friedberg JW, Rai K, O'Brien S. The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood. 2015 May 07; 125(19):2915-22. PMID: 25755291.
    Citations: 23     Fields:    Translation:HumansCTClinical Trials
  88. Lanasa MC, Andritsos L, Brown JR, Gabrilove J, Caligaris-Cappio F, Ghia P, Larson RA, Kipps TJ, Leblond V, Milligan DW, Janssens A, Johnson AJ, Heerema NA, Bühler A, Stilgenbauer S, Devin J, Hallek M, Byrd JC, Grever MR. Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. Leuk Res. 2015 May; 39(5):495-500. PMID: 25804339.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  89. Arnason JE, Brown JR. Targeted therapy for chronic lymphocytic leukemia: current status and future directions. Drugs. 2015 Feb; 75(2):143-55. PMID: 25619739.
    Citations: 2     Fields:    Translation:HumansCells
  90. Landau DA, Clement K, Ziller MJ, Boyle P, Fan J, Gu H, Stevenson K, Sougnez C, Wang L, Li S, Kotliar D, Zhang W, Ghandi M, Garraway L, Fernandes SM, Livak KJ, Gabriel S, Gnirke A, Lander ES, Brown JR, Neuberg D, Kharchenko PV, Hacohen N, Getz G, Meissner A, Wu CJ. Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. Cancer Cell. 2014 Dec 08; 26(6):813-825. PMID: 25490447.
    Citations: 59     Fields:    Translation:HumansCells
  91. Brown JR. Idelalisib for chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2014 Dec; 12(12):846-8. PMID: 25674842.
    Citations: 2     Fields:    Translation:Humans
  92. Strati P, Tong WG, Vitale C, Wierda WG, O'Brien S, Brown JR, Weng WK, Kipps T, Keating MJ, Ferrajoli A. A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2015 Jun; 56(6):1878-80. PMID: 25311497.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  93. Jacobsen E, Pozdnyakova O, Redd R, Fisher DC, Dorfman DM, Dal Cin P, LaCasce A, Armand P, Hochberg E, Cote G, Shahsafaei A, Neuberg D, Brown JR, Freedman AS. Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma. Leuk Lymphoma. 2015 Apr; 56(4):993-8. PMID: 25012943.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  94. Shindiapina P, Brown JR, Danilov AV. A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53. Br J Haematol. 2014 Oct; 167(2):149-61. PMID: 25040077.
    Citations: 6     Fields:    Translation:HumansCells
  95. Rendleman J, Antipin Y, Reva B, Adaniel C, Przybylo JA, Dutra-Clarke A, Hansen N, Heguy A, Huberman K, Borsu L, Paltiel O, Ben-Yehuda D, Brown JR, Freedman AS, Sander C, Zelenetz A, Klein RJ, Shao Y, Lacher M, Vijai J, Offit K, Kirchhoff T. Genetic variation in DNA repair pathways and risk of non-Hodgkin's lymphoma. PLoS One. 2014; 9(7):e101685. PMID: 25010664.
    Citations: 2     Fields:    Translation:HumansCells
  96. Kwiatkowski N, Zhang T, Rahl PB, Abraham BJ, Reddy J, Ficarro SB, Dastur A, Amzallag A, Ramaswamy S, Tesar B, Jenkins CE, Hannett NM, McMillin D, Sanda T, Sim T, Kim ND, Look T, Mitsiades CS, Weng AP, Brown JR, Benes CH, Marto JA, Young RA, Gray NS. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 2014 Jul 31; 511(7511):616-20. PMID: 25043025.
    Citations: 111     Fields:    Translation:HumansCells
  97. Brown JR, O'Brien SM, Barrientos JC, Kay NE, Reddy NM, Coutre SE, Tam C, Mulligan SP, Jäger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Fardis M, McGreivy JS, Clow F, James DF, Hillmen P. Randomized comparison of ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase III RESONATE trial. J Clin Oncol. 2014 Jun 20; 32(18_suppl):LBA7008. PMID: 28141976.
    Citations:    
  98. Baron KB, Brown JR, Heiss BL, Marshall J, Tait N, Tkaczuk KH, Gottlieb SS. Trastuzumab-induced cardiomyopathy: incidence and associated risk factors in an inner-city population. J Card Fail. 2014 Aug; 20(8):555-9. PMID: 24905295.
    Citations: 3     Fields:    Translation:Humans
  99. Brown JR, Wiestner A. Chronic lymphocytic leukemia: moving forward-rapidly. Semin Hematol. 2014 Jul; 51(3):157. PMID: 25048779.
    Citations:    Fields:    Translation:Humans
  100. Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014 Jul 17; 371(3):213-23. PMID: 24881631.
    Citations: 248     Fields:    Translation:Humans
  101. Sobecks RM, Leis JF, Gale RP, Ahn KW, Zhu X, Sabloff M, de Lima M, Brown JR, Inamoto Y, Hale GA, Aljurf MD, Kamble RT, Hsu JW, Pavletic SZ, Wirk B, Seftel MD, Lewis ID, Alyea EP, Cortes J, Kalaycio ME, Maziarz RT, Saber W. Outcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimens. Biol Blood Marrow Transplant. 2014 Sep; 20(9):1390-8. PMID: 24880021.
    Citations: 3     Fields:    Translation:Humans
  102. James DF, Werner L, Brown JR, Wierda WG, Barrientos JC, Castro JE, Greaves A, Johnson AJ, Rassenti LZ, Rai KR, Neuberg D, Kipps TJ. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. J Clin Oncol. 2014 Jul 01; 32(19):2067-73. PMID: 24868031.
    Citations: 16     Fields:    Translation:Humans
  103. Claus R, Lucas DM, Ruppert AS, Williams KE, Weng D, Patterson K, Zucknick M, Oakes CC, Rassenti LZ, Greaves AW, Geyer S, Wierda WG, Brown JR, Gribben JG, Barrientos JC, Rai KR, Kay NE, Kipps TJ, Shields P, Zhao W, Grever MR, Plass C, Byrd JC. Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. Blood. 2014 Jul 03; 124(1):42-8. PMID: 24868078.
    Citations: 15     Fields:    Translation:HumansCells
  104. Davids MS, Brown JR. Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase. Future Oncol. 2014 May; 10(6):957-67. PMID: 24941982.
    Citations: 16     Fields:    Translation:HumansAnimals
  105. Wang L, Shalek AK, Lawrence M, Ding R, Gaublomme JT, Pochet N, Stojanov P, Sougnez C, Shukla SA, Stevenson KE, Zhang W, Wong J, Sievers QL, MacDonald BT, Vartanov AR, Goldstein NR, Neuberg D, He X, Lander E, Hacohen N, Regev A, Getz G, Brown JR, Park H, Wu CJ. Somatic mutation as a mechanism of Wnt/ß-catenin pathway activation in CLL. Blood. 2014 Aug 14; 124(7):1089-98. PMID: 24778153.
    Citations: 12     Fields:    Translation:HumansCells
  106. Wu H, Wang W, Liu F, Weisberg EL, Tian B, Chen Y, Li B, Wang A, Wang B, Zhao Z, McMillin DW, Hu C, Li H, Wang J, Liang Y, Buhrlage SJ, Liang J, Liu J, Yang G, Brown JR, Treon SP, Mitsiades CS, Griffin JD, Liu Q, Gray NS. Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma. ACS Chem Biol. 2014 May 16; 9(5):1086-91. PMID: 24556163.
    Citations: 12     Fields:    Translation:HumansCells
  107. Godbersen JC, Humphries LA, Danilova OV, Kebbekus PE, Brown JR, Eastman A, Danilov AV. The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-?B activation and induces apoptosis in chronic lymphocytic leukemia B cells. Clin Cancer Res. 2014 Mar 15; 20(6):1576-89. PMID: 24634471.
    Citations: 27     Fields:    Translation:HumansAnimalsCells
  108. Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, Spurgeon SE, Kahl BS, Bello C, Webb HK, Johnson DM, Peterman S, Li D, Jahn TM, Lannutti BJ, Ulrich RG, Yu AS, Miller LL, Furman RR. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110d, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014 May 29; 123(22):3390-7. PMID: 24615777.
    Citations: 149     Fields:    Translation:HumansCTClinical Trials
  109. Kahl BS, Spurgeon SE, Furman RR, Flinn IW, Coutre SE, Brown JR, Benson DM, Byrd JC, Peterman S, Cho Y, Yu A, Godfrey WR, Wagner-Johnston ND. A phase 1 study of the PI3Kd inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood. 2014 May 29; 123(22):3398-405. PMID: 24615778.
    Citations: 48     Fields:    Translation:HumansCTClinical Trials
  110. Flinn IW, Kahl BS, Leonard JP, Furman RR, Brown JR, Byrd JC, Wagner-Johnston ND, Coutre SE, Benson DM, Peterman S, Cho Y, Webb HK, Johnson DM, Yu AS, Ulrich RG, Godfrey WR, Miller LL, Spurgeon SE. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-d, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014 May 29; 123(22):3406-13. PMID: 24615776.
    Citations: 52     Fields:    Translation:HumansCTClinical Trials
  111. Velez NF, Karia PS, Vartanov AR, Davids MS, Brown JR, Schmults CD. Association of advanced leukemic stage and skin cancer tumor stage with poor skin cancer outcomes in patients with chronic lymphocytic leukemia. JAMA Dermatol. 2014 Mar; 150(3):280-7. PMID: 24429548.
    Citations: 4     Fields:    Translation:Humans
  112. Arnason JE, Brown JR. B cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292. Immunotargets Ther. 2014; 3:29-38. PMID: 27471698.
    Citations: 3     
  113. Brown JR, Porter DL, O'Brien SM. Novel treatments for chronic lymphocytic leukemia and moving forward. Am Soc Clin Oncol Educ Book. 2014; e317-25. PMID: 24857119.
    Citations: 3     Fields:    Translation:Humans
  114. Brown JR. A new era of treatment for chronic lymphocytic leukaemia? Lancet Oncol. 2014 Jan; 15(1):3-5. PMID: 24332240.
    Citations:    Fields:    Translation:Humans
  115. Sabloff M, Sobecks RM, Ahn KW, Zhu X, de Lima M, Brown JR, Inamoto Y, Holland HK, Aljurf MD, Laughlin MJ, Kamble RT, Hsu JW, Wirk BM, Seftel M, Lewis ID, Arora M, Alyea EP, Kalaycio ME, Cortes J, Maziarz RT, Gale RP, Saber W. Does total body irradiation conditioning improve outcomes of myeloablative human leukocyte antigen-identical sibling transplantations for chronic lymphocytic leukemia? Biol Blood Marrow Transplant. 2014 Mar; 20(3):421-4. PMID: 24321745.
    Citations: 4     Fields:    Translation:Humans
  116. Houldsworth J, Guttapalli A, Thodima V, Yan XJ, Mendiratta G, Zielonka T, Nanjangud G, Chen W, Patil S, Mato A, Brown JR, Rai K, Chiorazzi N, Chaganti RS. Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2014 Apr; 55(4):920-8. PMID: 24047479.
    Citations: 6     Fields:    Translation:HumansCells
  117. Pyo J, Won Kim K, Jacene HA, Sakellis CG, Brown JR, Van den Abbeele AD. End-therapy positron emission tomography for treatment response assessment in follicular lymphoma: a systematic review and meta-analysis. Clin Cancer Res. 2013 Dec 01; 19(23):6566-77. PMID: 24052020.
    Citations: 1     Fields:    Translation:Humans
  118. Burkhardt UE, Hainz U, Stevenson K, Goldstein NR, Pasek M, Naito M, Wu D, Ho VT, Alonso A, Hammond NN, Wong J, Sievers QL, Brusic A, McDonough SM, Zeng W, Perrin A, Brown JR, Canning CM, Koreth J, Cutler C, Armand P, Neuberg D, Lee JS, Antin JH, Mulligan RC, Sasada T, Ritz J, Soiffer RJ, Dranoff G, Alyea EP, Wu CJ. Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. J Clin Invest. 2013 Sep; 123(9):3756-65. PMID: 23912587.
    Citations: 23     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
  119. Brown JR. Inherited susceptibility to chronic lymphocytic leukemia: evidence and prospects for the future. Ther Adv Hematol. 2013 Aug; 4(4):298-308. PMID: 23926461.
    Citations: 1     
  120. Armand P, Oki Y, Neuberg DS, Faham M, Cummings C, Klinger M, Weng L, Bhattar S, Lacasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Fowler NH, Alma Rodriguez M, Wallace MJ, Neelapu SS, Rodig S, Younes A, Freedman AS. Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2013 Oct; 163(1):123-6. PMID: 23795711.
    Citations: 19     Fields:    Translation:HumansCells
  121. Brown JR. Ibrutinib in chronic lymphocytic leukemia and B cell malignancies. Leuk Lymphoma. 2014 Feb; 55(2):263-9. PMID: 23656200.
    Citations: 8     Fields:    Translation:HumansCells
  122. Brown JR. B-cell receptor inhibitors in chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2013 Jun; 11(6):362-4. PMID: 24472805.
    Citations:    Fields:    Translation:Humans
  123. Davids MS, Letai A, Brown JR. Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition. Leuk Lymphoma. 2013 Aug; 54(8):1823-5. PMID: 23614795.
    Citations: 11     Fields:    Translation:HumansCells
  124. Brown JR, Messmer B, Werner L, Davids MS, Mikler E, Supko JG, Fisher DC, LaCasce AS, Armand P, Jacobsen E, Dalton V, Tesar B, Fernandes SM, McDonough S, Ritz J, Rassenti L, Kipps TJ, Neuberg D, Freedman AS. A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica. 2013 Jun; 98(6):964-70. PMID: 23645694.
    Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
  125. Improgo MR, Brown JR. Genomic approaches to chronic lymphocytic leukemia. Hematol Oncol Clin North Am. 2013 Apr; 27(2):157-71. PMID: 23561468.
    Citations: 1     Fields:    Translation:HumansCells
  126. Brown JR. Hematology/Oncology Clinics of North America. Chronic Lymphocytic Leukemia. Preface. Hematol Oncol Clin North Am. 2013 Apr; 27(2):xiii-xiv. PMID: 23561479.
    Citations: 1     Fields:    Translation:Humans
  127. Davids MS, Brown JR. Phosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemia. Hematol Oncol Clin North Am. 2013 Apr; 27(2):329-39. PMID: 23561476.
    Citations: 1     Fields:    Translation:HumansAnimals
  128. Brown JR. Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials. Curr Hematol Malig Rep. 2013 Mar; 8(1):1-6. PMID: 23296407.
    Citations: 23     Fields:    Translation:Humans
  129. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, Sougnez C, Stewart C, Sivachenko A, Wang L, Wan Y, Zhang W, Shukla SA, Vartanov A, Fernandes SM, Saksena G, Cibulskis K, Tesar B, Gabriel S, Hacohen N, Meyerson M, Lander ES, Neuberg D, Brown JR, Getz G, Wu CJ. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013 Feb 14; 152(4):714-26. PMID: 23415222.
    Citations: 397     Fields:    Translation:HumansAnimalsCells
  130. Abramson JS, Takvorian RW, Fisher DC, Feng Y, Jacobsen ED, Brown JR, Barnes JA, Neuberg DS, Hochberg EP. Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study. Leuk Lymphoma. 2013 Sep; 54(9):1915-20. PMID: 23289359.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  131. Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y, Liu X, Morra E, Trojani A, Greco A, Arcaini L, Varettoni M, Varettoni M, Brown JR, Tai YT, Anderson KC, Munshi NC, Patterson CJ, Manning RJ, Tripsas CK, Lindeman NI, Treon SP. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013 Mar 14; 121(11):2051-8. PMID: 23321251.
    Citations: 69     Fields:    Translation:HumansCells
  132. Armand P, Welch S, Kim HT, LaCasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Coughlin E, Freedman AS, Chen YB. Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era. Br J Haematol. 2013 Mar; 160(5):608-17. PMID: 23278720.
    Citations: 10     Fields:    Translation:Humans
  133. Brown JR. Gastric mucosa-associated lymphoid tissue lymphoma resistant to Helicobacter pylori eradication: what's the best option? Leuk Lymphoma. 2013 May; 54(5):899-900. PMID: 23127114.
    Citations:    Fields:    Translation:Humans
  134. Shalek AK, Gaublomme JT, Wang L, Yosef N, Chevrier N, Andersen MS, Robinson JT, Pochet N, Neuberg D, Gertner RS, Amit I, Brown JR, Hacohen N, Regev A, Wu CJ, Park H. Nanowire-mediated delivery enables functional interrogation of primary immune cells: application to the analysis of chronic lymphocytic leukemia. Nano Lett. 2012 Dec 12; 12(12):6498-504. PMID: 23190424.
    Citations: 17     Fields:    Translation:HumansAnimalsCells
  135. Davids MS, Brown JR. Targeting the B cell receptor pathway in chronic lymphocytic leukemia. Leuk Lymphoma. 2012 Dec; 53(12):2362-70. PMID: 22616724.
    Citations: 21     Fields:    Translation:HumansAnimalsCells
  136. Davids MS, Deng J, Wiestner A, Lannutti BJ, Wang L, Wu CJ, Wilson WH, Brown JR, Letai A. Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood. 2012 Oct 25; 120(17):3501-9. PMID: 22955911.
    Citations: 43     Fields:    Translation:HumansCells
  137. Brown JR, Kim HT, Armand P, Cutler C, Fisher DC, Ho V, Koreth J, Ritz J, Wu C, Antin JH, Soiffer RJ, Gribben JG, Alyea EP. Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. Leukemia. 2013 Feb; 27(2):362-9. PMID: 22955330.
    Citations: 27     Fields:    Translation:Humans
  138. Zhang Y, Roccaro AM, Rombaoa C, Flores L, Obad S, Fernandes SM, Sacco A, Liu Y, Ngo H, Quang P, Azab AK, Azab F, Maiso P, Reagan M, Brown JR, Thai TH, Kauppinen S, Ghobrial IM. LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas. Blood. 2012 Aug 23; 120(8):1678-86. PMID: 22797699.
    Citations: 41     Fields:    Translation:HumansAnimalsCells
  139. Dutta C, Day T, Kopp N, van Bodegom D, Davids MS, Ryan J, Bird L, Kommajosyula N, Weigert O, Yoda A, Fung H, Brown JR, Shapiro GI, Letai A, Weinstock DM. BCL2 suppresses PARP1 function and nonapoptotic cell death. Cancer Res. 2012 Aug 15; 72(16):4193-203. PMID: 22689920.
    Citations: 12     Fields:    Translation:HumansAnimalsCells
  140. Brown JR, Hanna M, Tesar B, Werner L, Pochet N, Asara JM, Wang YE, Dal Cin P, Fernandes SM, Thompson C, Macconaill L, Wu CJ, Van de Peer Y, Correll M, Regev A, Neuberg D, Freedman AS. Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia. Clin Cancer Res. 2012 Jul 15; 18(14):3791-802. PMID: 22623730.
    Citations: 22     Fields:    Translation:HumansCells
  141. Landrum MB, Keating NL, Lamont EB, Bozeman SR, Krasnow SH, Shulman L, Brown JR, Earle CC, Rabin M, McNeil BJ. Survival of older patients with cancer in the Veterans Health Administration versus fee-for-service Medicare. J Clin Oncol. 2012 Apr 01; 30(10):1072-9. PMID: 22393093.
    Citations: 20     Fields:    Translation:Humans
  142. Lane AA, Armand P, Feng Y, Neuberg DS, Abramson JS, Brown JR, Fisher DC, LaCasce AS, Jacobsen ED, McAfee SL, Spitzer TR, Freedman AS, Chen YB. Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant. Leuk Lymphoma. 2012 Jun; 53(6):1130-6. PMID: 22132836.
    Citations: 3     Fields:    Translation:Humans
  143. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, Carney DA, He SZ, Huang DC, Xiong H, Cui Y, Busman TA, McKeegan EM, Krivoshik AP, Enschede SH, Humerickhouse R. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012 Feb 10; 30(5):488-96. PMID: 22184378.
    Citations: 216     Fields:    Translation:HumansCTClinical Trials
  144. Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K, Werner L, Sivachenko A, DeLuca DS, Zhang L, Zhang W, Vartanov AR, Fernandes SM, Goldstein NR, Folco EG, Cibulskis K, Tesar B, Sievers QL, Shefler E, Gabriel S, Hacohen N, Reed R, Meyerson M, Golub TR, Lander ES, Neuberg D, Brown JR, Getz G, Wu CJ. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011 Dec 29; 365(26):2497-506. PMID: 22150006.
    Citations: 322     Fields:    Translation:HumansCells
  145. Ge X, Wu L, Hu W, Fernandes S, Wang C, Li X, Brown JR, Qin X. rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia. Clin Cancer Res. 2011 Nov 01; 17(21):6702-11. PMID: 21918174.
    Citations: 16     Fields:    Translation:HumansCells
  146. Keating NL, Landrum MB, Lamont EB, Bozeman SR, Krasnow SH, Shulman LN, Brown JR, Earle CC, Oh WK, Rabin M, McNeil BJ. Quality of care for older patients with cancer in the Veterans Health Administration versus the private sector: a cohort study. Ann Intern Med. 2011 Jun 07; 154(11):727-36. PMID: 21646556.
    Citations: 28     Fields:    Translation:Humans
  147. Brown JR. Insulin receptor activation in deletion 11q chronic lymphocytic leukemia. Clin Cancer Res. 2011 May 01; 17(9):2605-7. PMID: 21427241.
    Citations: 2     Fields:    Translation:HumansCells
  148. Amrein PC, Attar EC, Takvorian T, Hochberg EP, Ballen KK, Leahy KM, Fisher DC, Lacasce AS, Jacobsen ED, Armand P, Hasserjian RP, Werner L, Neuberg D, Brown JR. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2011 May 01; 17(9):2977-86. PMID: 21402714.
    Citations: 42     Fields:    Translation:HumansCTClinical Trials
  149. Li S, Moffett HF, Lu J, Werner L, Zhang H, Ritz J, Neuberg D, Wucherpfennig KW, Brown JR, Novina CD. MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells. PLoS One. 2011 Mar 08; 6(3):e16956. PMID: 21408091.
    Citations: 27     Fields:    Translation:HumansCells
  150. Hu W, Ge X, You T, Xu T, Zhang J, Wu G, Peng Z, Chorev M, Aktas BH, Halperin JA, Brown JR, Qin X. Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis. Cancer Res. 2011 Mar 15; 71(6):2298-307. PMID: 21252115.
    Citations: 23     Fields:    Translation:HumansAnimalsCells
  151. Arnason JE, Brown JR. Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia. [corrected]. Hematology Am Soc Hematol Educ Program. 2011; 2011:119-20. PMID: 22160022.
    Citations: 1     Fields:    Translation:HumansCells
  152. Brown JR. The treatment of relapsed refractory chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2011; 2011:110-8. PMID: 22160021.
    Citations: 18     Fields:    Translation:Humans
  153. Abou-Nassar K, Brown JR. Novel agents for the treatment of chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2010 Dec; 8(12):886-95. PMID: 21326166.
    Citations: 8     Fields:    Translation:Humans
  154. Heerema NA, Byrd JC, Dal Cin PS, Dell' Aquila ML, Koduru PR, Aviram A, Smoley SA, Rassenti LZ, Greaves AW, Brown JR, Rai KR, Kipps TJ, Kay NE, Van Dyke DL. Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) Study. Cancer Genet Cytogenet. 2010 Dec; 203(2):134-40. PMID: 21156225.
    Citations: 9     Fields:    Translation:HumansCells
  155. Smoley SA, Van Dyke DL, Kay NE, Heerema NA, Dell' Aquila ML, Dal Cin P, Koduru P, Aviram A, Rassenti L, Byrd JC, Rai KR, Brown JR, Greaves AW, Eckel-Passow J, Neuberg D, Kipps TJ, Dewald GW. Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium. Cancer Genet Cytogenet. 2010 Dec; 203(2):141-8. PMID: 21156226.
    Citations: 5     Fields:    Translation:HumansCells
  156. Friese CR, Earle CC, Magazu LS, Brown JR, Neville BA, Hevelone ND, Richardson LC, Abel GA. Timeliness and quality of diagnostic care for medicare recipients with chronic lymphocytic leukemia. Cancer. 2011 Apr 01; 117(7):1470-7. PMID: 21425148.
    Citations: 8     Fields:    Translation:Humans
  157. Wierda WG, Chiorazzi N, Dearden C, Brown JR, Montserrat E, Shpall E, Stilgenbauer S, Muneer S, Grever M. Chronic lymphocytic leukemia: new concepts for future therapy. Clin Lymphoma Myeloma Leuk. 2010 Oct; 10(5):369-78. PMID: 21030350.
    Citations: 4     Fields:    Translation:Humans
  158. Danilov AV, Danilova OV, Brown JR, Rabinowitz A, Klein AK, Huber BT. Dipeptidyl peptidase 2 apoptosis assay determines the B-cell activation stage and predicts prognosis in chronic lymphocytic leukemia. Exp Hematol. 2010 Dec; 38(12):1167-77. PMID: 20817072.
    Citations: 4     Fields:    Translation:HumansCells
  159. Setlur SR, Ihm C, Tchinda J, Shams S, Werner L, Cho EK, Thompson C, Phillips K, Rassenti LZ, Kipps TJ, Neuberg D, Freedman AS, Lee C, Brown JR. Comparison of familial and sporadic chronic lymphocytic leukaemia using high resolution array comparative genomic hybridization. Br J Haematol. 2010 Nov; 151(4):336-45. PMID: 20812997.
    Citations: 6     Fields:    Translation:HumansCells
  160. Wierda WG, Kipps TJ, Keating MJ, Brown JR, Gribben JG, Browning M, Rassenti LZ, Greaves AW, Neuberg D, O'Brien SM. Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. Cancer. 2011 Jan 01; 117(1):116-24. PMID: 20806349.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  161. Brown JR. Immunomodulators in chronic lymphocytic leukemia: where does lenalidomide belong? Leuk Lymphoma. 2010 Aug; 51(8):1382-5. PMID: 20624030.
    Citations: 2     Fields:    Translation:HumansAnimals
  162. Yoda A, Yoda Y, Chiaretti S, Bar-Natan M, Mani K, Rodig SJ, West N, Xiao Y, Brown JR, Mitsiades C, Sattler M, Kutok JL, DeAngelo DJ, Wadleigh M, Piciocchi A, Dal Cin P, Bradner JE, Griffin JD, Anderson KC, Stone RM, Ritz J, Foà R, Aster JC, Frank DA, Weinstock DM. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2010 Jan 05; 107(1):252-7. PMID: 20018760.
    Citations: 92     Fields:    Translation:HumansCells
  163. Brown JR, Freedman AS. ASCT in follicular lymphoma. Nat Rev Clin Oncol. 2009 Jul; 6(7):380-2. PMID: 19561632.
    Citations:    Fields:    Translation:Humans
  164. Brown JR, Friedberg JW, Feng Y, Scofield S, Phillips K, Dal Cin P, Joyce R, Takvorian RW, Fisher DC, Fisher RI, Liesveld J, Marquis D, Neuberg D, Freedman AS. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol. 2009 Jun; 145(6):741-8. PMID: 19344412.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  165. Armand P, Gannamaneni S, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Antin JH. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol. 2008 Dec 10; 26(35):5767-74. PMID: 19001324.
    Citations: 41     Fields:    Translation:Humans
  166. Brown JR. Inherited predisposition to chronic lymphocytic leukemia. Expert Rev Hematol. 2008 Oct; 1(1):51-61. PMID: 19802369.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  167. Brown JR, Neuberg D, Phillips K, Reynolds H, Silverstein J, Clark JC, Ash M, Thompson C, Fisher DC, Jacobsen E, LaCasce AS, Freedman AS. Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders. Br J Haematol. 2008 Nov; 143(3):361-8. PMID: 18729853.
    Citations: 8     Fields:    Translation:Humans
  168. Rassenti LZ, Jain S, Keating MJ, Wierda WG, Grever MR, Byrd JC, Kay NE, Brown JR, Gribben JG, Neuberg DS, He F, Greaves AW, Rai KR, Kipps TJ. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood. 2008 Sep 01; 112(5):1923-30. PMID: 18577710.
    Citations: 96     Fields:    Translation:Humans
  169. Ruddy KJ, Wu D, Brown JR. Pseudohyperkalemia in chronic lymphocytic leukemia. J Clin Oncol. 2008 Jun 01; 26(16):2781-2. PMID: 18509189.
    Citations: 7     Fields:    Translation:Humans
  170. Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Alyea EP. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant. 2008 Apr; 14(4):418-25. PMID: 18342784.
    Citations: 37     Fields:    Translation:Humans
  171. Ghia EM, Jain S, Widhopf GF, Rassenti LZ, Keating MJ, Wierda WG, Gribben JG, Brown JR, Rai KR, Byrd JC, Kay NE, Greaves AW, Kipps TJ. Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. Blood. 2008 May 15; 111(10):5101-8. PMID: 18326815.
    Citations: 17     Fields:    Translation:HumansCells
  172. Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2008 Jan 10; 26(2):196-203. PMID: 18182662.
    Citations: 30     Fields:    Translation:HumansCTClinical Trials
  173. Ruddy KJ, Wu D, Brown JR. Pseudohyperkalemia in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. 2008; In Press..
  174. Chen YB, Yu H, Gillani A, Brown JR. AIDS-associated plasmablastic lymphoma presenting at the insertion site of a peritoneal dialysis catheter. J Clin Oncol. 2007 Jul 20; 25(21):3176-8. PMID: 17634499.
    Citations: 1     Fields:    Translation:Humans
  175. Brown JR, Feng Y, Gribben JG, Neuberg D, Fisher DC, Mauch P, Nadler LM, Freedman AS. Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant. 2007 Sep; 13(9):1057-65. PMID: 17697968.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  176. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest. 2007 Jan; 117(1):112-21. PMID: 17200714.
    Citations: 205     Fields:    Translation:HumansCells
  177. Brown JR. Richter's Transformation: Pathobiology and Treatment. In: UpToDate, Rose, B.D., Ed. 2007.
  178. Ghia EM, Rassenti LZ, Widhopf GF, Silverman GJ, Neuberg DS, Keating MJ, Wierda WG, Gribben JG, Brown JR, Rai KR, Byrd JC, Kay NE, Greaves AW, Kipps TJ. . Stereotypic IGHV3-21/IGLV3-21 Antibodies Expressed in High-Risk Chronic Lymphocytic Leukemia Bind Peptostreptococcus Magnus Protein L. Blood. 2007; 110:227a.
  179. Brown JR, Friedberg J, Feng Y, Phillips K, Clark JC, dal Cin P, Joyce R, Fisher DC, Fisher RI, Takvorian RW, Liesveld J, Marquis D, Neuberg D, Freedman AS. . A Phase 2 Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Lymphomas. Blood. 2007; 110:408a.
  180. Rassenti LR, Huynh L, Basak GW, Ghia EM, Van Dyke D, Heerema N, Zahrieh D, Dal Cin P, Dell’Aquila ML, Koduru P, Byrd JC, Kay NE, Rai KR, Brown JR, Wierda WW, Greaves AW, Kipps TJ. TCL1 Expression in Chronic Lymphocytic Leukemia Correlates with the Intensity of 11q Deletions and ZAP70. Blood. 2007; 110:616a.
  181. Flowers C, Rosenthal H, Brown J, Stock W, Katzen H, Lakhanpal S, Jaye D. . Analysis of Minimal Residual Disease (MRD) from the Phase 2 Multicenter Study of Subcutaneous (SC) Alemtuzumab Combined with Fludarabine for Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (CLL). Blood. 2007; 110:951a.
  182. Brown JR, Levine RL, Raderschall E, Thompson C, Gilliland DG, Freedman AS. Systematic Genomic Screen for Tyrosine Kinase Mutations in CLL. Blood. 2007; 110:616a.
  183. Ghobrial IM, Leduc R, Nelson M, Leleu X, Jacobsen ED, Lacasce AS, DeAngelo D, Fisher DC, Brown JR, Schlossman R, Warren D, Soumerai J, O’Connor K, Munshi N, Richardson P, Anderson KC, Witzig TE, Treon SP. . Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results. Blood. 2007; 110:4496a.
  184. Chen Y-B, Yu H, Gillani A, Brown JR. AIDS-Associated Plasmablastic Lymphoma Presenting at the Insertion Site of a Peritoneal Dialysis Catheter. Journal of Clinical Oncology. 2007; 25:3176-3178.
  185. Brown JR, Neuberg DS, Phillips K, Silverstein J, Clark JC, Raderschall E, Thompson C, Freedman AS. . Prevalence of Familial Malignancy in a Prospectively Screened Cohort of Patients with CLL and Lymphoproliferative Disorders. Leukemia and Lymphoma. 2007; 48(Suppl 1):S141.
  186. Rassenti LZ, Neuberg DS, Jain S, Huynh L, Wierda WG, Gribben JG, Brown JR, Flinn IW, Rai KR, Byrd JC, Grever MR, Kay NE, Greaves AW, Kipps TJ. Relative Value of ZAP70, CD38 and Immunoglobulin Mutation Status in Predicting Disease Progression in Chronic Lymphocytic Leukemia. Leukemia and Lymphoma. 2007; 48(Suppl 1):S90.
  187. Brown JR, Rastarhuyeva I, Jagannathan J, Stevenson K, Neuberg DS, Melenevsky Y, Phillips KS, Clark JC, Takvorian RW, Fisher DC, Freedman AS, Van den Abbeele AD. Prospective Evaluation of FDG-PET Imaging of Treatment Response in Relapsed Follicular Lymphoma. Blood. 2007; 110:689a.
  188. Amrein PC, Attar EC, Takvorian T, Hochberg EP, Ballen K, Zahrieh D, Brown JR. A Phase II Study of Dasatinib in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL/SLL). Blood. 2007; 110:920a.
  189. Flowers C, Brown J, Stock W, Katzen H, Lakhanpal S, Leis J, on behalf of ECO-1 Study. Interim Safety and Efficacy Results from the Phase 2 Multicenter Study of Subcutaneous Alemtuzumab Combined with Fludarabine for the Treatment of Relapsed/Refractory B-cell CLL. Leukemia and Lymphoma. 2007; 48(Suppl 1):S175.
  190. Brown JR, Gribben JG, Feng Y, Neuberg D, Mauch P, Nadler LM, Freedman AS. Long-Term Follow-Up of Autologous Bone Marrow Transplantation for Follicular Lymphoma in First Remission: Bone Marrow Involvement at Harvest and PCR Detectable Disease after Ex Vivo Purging Predict Relapse. Blood. 2006; 108(11):865a.
  191. Wierda WG, Kipps TJ, Keating MJ, Brown JR, Gribben JG, Browning ML, Rassenti LZ, Greaves AW, Neuberg D, O’Brien SM. . Self-Administered, Subcutaneous (SQ) Alemtuzumab To Eliminate Residual Disease in Patients with CLL. Blood. 2006; 108(11):804a.
  192. Brown JR, Phillips KS, Neuberg D, Raderschall E, Freedman AS. Prevalence of Familial Lymphoproliferative Malignancy in a Prospectively Screened Cohort of Patients with Lymphoproliferative Disorders. Blood. 2006; 108(11):246a.
  193. Tsimberidou AM, Wierda WG, O’Brien S, Plunkett WW, Kipps TJ, Brown JR, Lerner S, Kantarjian H, Keating MJ. . Combination of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Richter’s Syndrome and Fludarabine-Refractory Chronic Lymphocytic Leukemia. Blood. 2006; 108(11):799a.
  194. Rassenti LZ, Neuberg DS, Huynh L, Wierda WG, Gribben JG, Brown JR, Flinn IW, Rai KR, Byrd JC, Kay NE, Greaves AW, Kipps TJ. . Relative Value of CD38 and ZAP-70 Versus Immunoglobulin Mutation Status in Predicting Early Disease Progression in Chronic Lymphocytic Leukemia. Blood. 2006; 108(11):786a.
  195. Ghia EM, Rassenti LZ, Widhopf GF, Neuberg DS, Keating MJ, Wierda WG, Gribben JG, Brown JR, Flinn IW, Rai KR, Byrd JC, Kay NE, Greaves AW, Kipps TJ. Study of VH3-21 in a Large Cohort of Chronic Lymphocytic Leukemia Patients Reveals Evidence for Antigen Selection and Confirms Its Predictive Value for Early Disease Progression. Blood. 2006; 108(11):785a.
  196. Brown JR, Stock W, Katzen HI, Suarez AJ, Lakhanpal S, Leis JF, Flowers C, on behalf of the ECO-1 Study Investigators. Early Estimates of Safety for Alemtuzumab Combined with Fludarabine for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia: Phase II Multicenter Study. Blood. 2006; 108(11):336b.
  197. Brown JR, Kim HT, Li S, Stephans K, Fisher DC, Cutler C, Ho V, Lee SJ, Milford EL, Ritz J, Antin JH, Soiffer RJ, Gribben JG, Alyea EP. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant. 2006 Oct; 12(10):1056-64. PMID: 17084369.
    Citations: 22     Fields:    Translation:Humans
  198. Khan KD, O’Brien S, Rai KR, Brown JR, Cook P, Maddox AM, Duarte AM, Haltom EJ, Uprichard MJ. . Phase 2 Study of Talabostat and Rituximab in Patients with Advanced Chronic Lymphocytic Leukemia (CLL) Previously Treated with a Rituximab/Fludarabine Regimen. Journal of Clinical Oncology. 2006; 24(18S):6598.
  199. Brown JR, Skarin AT. Differential Diagnosis. Canellos GP, Lister AT, Young B, Eds. The Lymphomas. 2006; 158-66.
  200. Brown JR, Skarin AT. Paraneoplastic Syndromes. Canellos GP, Lister AT, Young B, Eds. The Lymphomas. 2006; 139-46.
  201. Khan KD, O’Brien S, Rai KR, Brown JR, Cook P, Maddox AM, Duarte AM, Haltom EJ, Uprichard MJ. Phase 2 Study of Talabostat and Rituximab in Patients with Advanced Chronic Lymphocytic Leukemia (CLL) Previously Treated with a Rituximab/Fludarabine Regimen. Blood. 2005; 106(11):601a.
  202. Darabi K, Brown JR, Kao GS. Paradoxical embolism after peripheral blood stem cell infusion. Bone Marrow Transplant. 2005 Sep; 36(6):561-2. PMID: 16007104.
    Citations: 2     Fields:    Translation:Humans
  203. Brown JR. Chronic lymphocytic leukemia: a niche for flavopiridol? Clin Cancer Res. 2005 Jun 01; 11(11):3971-3. PMID: 15930331.
    Citations: 3     Fields:    Translation:Humans
  204. Brown JR, Yeckes H, Friedberg JW, Neuberg D, Kim H, Nadler LM, Freedman AS. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 2005 Apr 01; 23(10):2208-14. PMID: 15753460.
    Citations: 24     Fields:    Translation:Humans
  205. Brown JR and Freedman AS. Pathobiology of T Cell Non Hodgkin’s Lymphomas. In: UpToDate, Rose, B.D. Ed. 2005.
  206. Brown JR and Freedman AS. Pathobiology of the Aggressive and Highly Aggressive Non Hodgkin’s Lymphomas. In: UpToDate, Rose, B.D. Ed. 2005.
  207. Brown JR and Freedman AS. . Pathobiology of the Indolent Non Hodgkin’s Lymphomas. In: UpToDate, Rose, B.D. Ed. 2005.
  208. Brown JR and Freedman AS. Secondary Solid Tumors after Autologous Bone Marrow Transplantation for Non-Hodgkin’s Lymphoma. American Journal of Oncology Review. 2005; 4:530-3.
  209. Figueroa BE, Brown JR, Nascimento A, Fisher DC, Tuli S. Unusual sites of Hodgkin's lymphoma: CASE 2. Hodgkin's lymphoma of the CNS masquerading as meningioma. J Clin Oncol. 2004 Oct 15; 22(20):4228-30. PMID: 15483035.
    Citations: 5     Fields:    Translation:Humans
  210. Brown JR, Weng AP, Freedman AS. Hodgkin disease associated with T-cell non-Hodgkin lymphomas: case reports and review of the literature. Am J Clin Pathol. 2004 May; 121(5):701-8. PMID: 15151210.
    Citations: 4     Fields:    Translation:Humans
  211. Brown JR, Gaudet G, Friedberg JW, Neuberg D, Mauch P, Kutok JL, Takvorian T, Fisher DC, Gribben JG, Kim H, Nadler LM, Freedman AS. Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphoma. Leuk Lymphoma. 2004 Feb; 45(2):315-20. PMID: 15101717.
    Citations: 3     Fields:    Translation:HumansCells
  212. Brown JR, Skarin AT. Clinical mimics of lymphoma. Oncologist. 2004; 9(4):406-16. PMID: 15266094.
    Citations: 10     Fields:    Translation:Humans
  213. Brown JR, Wieczorek TJ, Shaffer K, Salgia R. Small-cell cancers, and an unusual reaction to chemotherapy. Case 1. Extrapulmonary small-cell carcinoma arising in the prostate. J Clin Oncol. 2003 Jun 15; 21(12):2437-8. PMID: 12805344.
    Citations: 3     Fields:    Translation:Humans
  214. Brown JR, Harris NL, Freedman AS. . Castleman’s Disease. In: UpToDate, Rose, B.D. Ed. 2003.
  215. Brown JR, Demetri GD. Challenges in the development of platelet growth factors: low expectations for low counts. Curr Hematol Rep. 2002 Nov; 1(2):110-8. PMID: 12901132.
    Citations: 3     Fields:    Translation:HumansCells
  216. Brown JR, Tiffany N, Grant R. . Anemia. Basch EM, Birnbaum SL, Garza C, Messersmith W, editors. The MGH Primer of Outpatient Medicine. 2002; 235-40.
  217. Yee A, Brown JR, Chan A. Anticoagulation. Basch EM, Birnbaum SL, Garza C, Messersmith W, editors. The MGH Primer of Outpatient Medicine. 2002; 241-6.
  218. Brown JR, Kuter DJ. The effect of unfractionated vs. low molecular weight heparin on tissue factor pathway inhibitor levels in hospital inpatients. Thromb Haemost. 2001 Jun; 85(6):979-85. PMID: 11434705.
    Citations: 1     Fields:    Translation:Humans
  219. Brown JR, Nigh E, Lee RJ, Ye H, Thompson MA, Saudou F, Pestell RG, Greenberg ME. Fos family members induce cell cycle entry by activating cyclin D1. Mol Cell Biol. 1998 Sep; 18(9):5609-19. PMID: 9710644.
    Citations: 59     Fields:    Translation:AnimalsCells
  220. Hiroi N, Marek GJ, Brown JR, Ye H, Saudou F, Vaidya VA, Duman RS, Greenberg ME, Nestler EJ. Essential role of the fosB gene in molecular, cellular, and behavioral actions of chronic electroconvulsive seizures. J Neurosci. 1998 Sep 01; 18(17):6952-62. PMID: 9712664.
    Citations: 32     Fields:    Translation:AnimalsCells
  221. Hiroi N, Brown JR, Haile CN, Ye H, Greenberg ME, Nestler EJ. FosB mutant mice: loss of chronic cocaine induction of Fos-related proteins and heightened sensitivity to cocaine's psychomotor and rewarding effects. Proc Natl Acad Sci U S A. 1997 Sep 16; 94(19):10397-402. PMID: 9294222.
    Citations: 60     Fields:    Translation:Animals
  222. Brown JR, Ye H, Bronson RT, Dikkes P, Greenberg ME. A defect in nurturing in mice lacking the immediate early gene fosB. Cell. 1996 Jul 26; 86(2):297-309. PMID: 8706134.
    Citations: 51     Fields:    Translation:Animals
  223. Brown JR. The Role of Fos Family Genes in Adaptive Neuronal Responses and Cell Proliferation [PhD Dissertation]. 1996.